A 25-year-old male with asthma on daily use of a short-acting beta agonist; most appropriate addition to regimen?

• A. Methylxanthine oxidase inhibitor
• B. Long acting beta agonist inhaler
• C. Leukotriene inhibitor
• D. Inhaled corticosteroid

Answer: (D)

When asthma is managed with daily use of a rescue inhaler, it shows the disease is not well controlled and a controller medication is needed to address the underlying inflammation. The inhaled corticosteroid is the best first add-on because it targets this inflammation directly, leading to fewer symptoms, better lung function, and fewer exacerbations over time. It changes the course of the disease by reducing airway hyperresponsiveness and the frequency of attacks, which daily SABA use alone cannot accomplish.

Other options exist but are not as effective as a first-line controller. A long-acting beta-agonist is useful when symptoms persist despite an inhaled corticosteroid, but starting with a controller that tackles inflammation is the priority. Leukotriene inhibitors can help some patients, especially with particular triggers or comorbidities, yet they don’t address inflammation as robustly as inhaled corticosteroids. Theophylline-based therapies are older and have a narrow safety window with many interactions, making them less favorable as an initial step.

Inhaled corticosteroids are generally well tolerated at recommended doses, but it’s good to use a spacer and rinse the mouth after inhalation to reduce the risk of oral thrush.